Lobe‐Specific Versus Systematic Lymph Node Dissection in Clinical Stage I Non‐Small Cell Lung Cancer: A Propensity Score‐Matched Analysis Based on the 8th Edition of the TNM Stage Classification
Thoracic Cancer · 2026-07 · 17 (13)
DOI: 10.1111/1759-7714.70337 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 29.06.2026. Verfasst von Hirotsugu Notsuda und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lymph Node Excision, Lung Neoplasms, Pneumonectomy. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The optimal extent of lymph node dissection (LND) in early‐stage non–small cell lung cancer (NSCLC) remains controversial. This study aimed to compare perioperative and oncological outcomes between lobe‐specific LND (LSD) and systematic LND (SND) in patients with clinical stage I NSCLC based on the 8th edition of the TNM classification.
Methods
We retrospectively analyzed 390 patients with clinical stage I NSCLC who underwent lobectomy with LND between 2010 and 2020. Patients with tumors in the right middle lobe or left lingular segment were excluded. Propensity score matching (PSM; 1:1 nearest‐neighbor matching) was performed using clinical and radiological covariates, yielding 140 matched patients in each group. Perioperative outcomes, postoperative complications (Clavien–Dindo grade ≥ II, with postoperative pneumonitis assessed according to CTCAE version 5.0), overall survival (OS), relapse‐free survival (RFS), and recurrence patterns were compared.
Results
After PSM, the LSD group had significantly shorter operative time, less blood loss, and shorter durations of chest tube placement and postoperative hospital stay than the SND group (all p < 0.05). Postoperative supraventricular tachyarrhythmia occurred more frequently in the SND group (0.7% vs. 7.1%, p = 0.006), whereas other complications were comparable. There were no significant differences in OS or RFS before or after PSM. Recurrence rates and patterns, including ipsilateral lymph node recurrence, were comparable.
Conclusions
LSD appears to be an oncologically valid and less invasive alternative to SND in patients with clinical stage I NSCLC. LSD may reduce surgical invasiveness and postoperative morbidity without compromising survival or increasing the risk of recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Thoracic Surgery, Tohoku University Hospital, Sendai, Miyagi, Japan.
- Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan.
- Department of Thoracic Surgery, Tohoku Medical and Pharmaceutical University, Sendai, Miyagi, Japan.
ORCID-Profile: Sakiko Kumata, Tatsuaki Watanabe, Hisashi Oishi, Yoshinori Okada
Zitieren
APA
Notsuda, H., Onodera, K., Kumata, S., Kamata, S., Kawakami, T., Watanabe, T., Watanabe, Y., Hirama, T., Suzuki, T., Oishi, H., Niikawa, H., & Okada, Y. (2026). Lobe‐Specific Versus Systematic Lymph Node Dissection in Clinical Stage I Non‐Small Cell Lung Cancer: A Propensity Score‐Matched Analysis Based on the 8th Edition of the TNM Stage Classification. Thoracic Cancer, 17(13). https://doi.org/10.1111/1759-7714.70337
Vancouver
Notsuda H, Onodera K, Kumata S, Kamata S, Kawakami T, Watanabe T, et al. Lobe‐Specific Versus Systematic Lymph Node Dissection in Clinical Stage I Non‐Small Cell Lung Cancer: A Propensity Score‐Matched Analysis Based on the 8th Edition of the TNM Stage Classification. Thoracic Cancer. 2026;17(13). doi:10.1111/1759-7714.70337
BibTeX
@article{Notsuda2026,
author = {Notsuda, Hirotsugu and Onodera, Ken and Kumata, Sakiko and Kamata, Satoshi and Kawakami, Toru and Watanabe, Tatsuaki and Watanabe, Yui and Hirama, Takashi and Suzuki, Takaya and Oishi, Hisashi and Niikawa, Hiromichi and Okada, Yoshinori},
title = {Lobe‐Specific Versus Systematic Lymph Node Dissection in Clinical Stage I Non‐Small Cell Lung Cancer: A Propensity Score‐Matched Analysis Based on the 8th Edition of the TNM Stage Classification},
journal = {Thoracic Cancer},
year = {2026},
volume = {17},
number = {13},
doi = {10.1111/1759-7714.70337}
}
EUVIMED